Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 6
1967 3
1968 8
1969 5
1970 12
1971 16
1972 24
1973 9
1974 18
1975 13
1976 13
1977 12
1978 20
1979 23
1980 24
1981 20
1982 25
1983 17
1984 18
1985 27
1986 16
1987 26
1988 32
1989 28
1990 29
1991 35
1992 36
1993 39
1994 43
1995 48
1996 39
1997 45
1998 67
1999 68
2000 100
2001 143
2002 136
2003 168
2004 174
2005 180
2006 170
2007 207
2008 213
2009 221
2010 280
2011 280
2012 272
2013 366
2014 368
2015 373
2016 307
2017 298
2018 274
2019 159
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

5,101 results
Results by year
Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, et al. N Engl J Med 2016 - Clinical Trial. PMID 27959607 Free article.
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. ...CONCLUSIONS: Among patients with moderately to severely active Crohn's disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. ...
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous indu …
Anti-TNF Therapy in Crohn's Disease.
Adegbola SO, et al. Int J Mol Sci 2018 - Review. PMID 30065229 Free PMC article.
Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. ...Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn's disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. ...
Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in th
Optimization of biologic therapy in Crohn's disease.
Razvi M and Lazarev M. Expert Opin Biol Ther 2018 - Review. PMID 29191059
INTRODUCTION: Crohn's disease (CD) is a manifestation of inflammatory bowel disease (IBD), which can result in significant morbidity. ...Drug level is also critical in determining if a patient requires combination therapy with an immunomodulator. Certain populations, including those with active perianal disease, may require higher serum levels to achieve healing or closure. ...
INTRODUCTION: Crohn's disease (CD) is a manifestation of inflammatory bowel disease (IBD), which can result in signific …
Therapy for Crohn's Disease: a Review of Recent Developments.
Eustace GJ and Melmed GY. Curr Gastroenterol Rep 2018 - Review. PMID 29623492
PURPOSE OF REVIEW: To review recent advances in the treatment of Crohn's disease. RECENT FINDINGS: Several key advances are highlighted, including the increasing role of treatment algorithms and where new therapies can be used most effectively, the appropriate use of therapeutic drug monitoring, optimal management of post-surgical patients, and the role of multi-disciplinary clinics. The last several years have seen a number of exciting developments in the field of Crohn's therapy. This review covers research advances including updated treatment algorithms focusing on identifying patient risk as well as the role of drug monitoring in managing the disease. ...
PURPOSE OF REVIEW: To review recent advances in the treatment of Crohn's disease. RECENT FINDINGS: Several key advances are hi …
Characteristics of biological therapy in pediatric patients with Crohn's disease.
Tarnok A, et al. Expert Opin Biol Ther 2019 - Review. PMID 30601083
INTRODUCTION: At present, there is a significant amount of data related to biologics used in pediatric patients with Crohn's disease. ...EXPERT COMMENTARY: There are significant data to characterize biological drugs administered in pediatric patients with Crohn's disease. ...
INTRODUCTION: At present, there is a significant amount of data related to biologics used in pediatric patients with Crohn's disea
Maintenance therapy for Crohn's disease: should it be indefinite?
Onal IK, et al. Eur J Gastroenterol Hepatol 2015 - Review. PMID 26181109
Crohn's disease (CD) is a chronic, persistent, and destructive disorder with different forms of clinical behavior and the disease appears to be progressive over the long term. ...This will often necessitate long-term therapy with immunosuppressant or biological therapies. Both these classes of drugs have side-effects and the latter are also very expensive. ...
Crohn's disease (CD) is a chronic, persistent, and destructive disorder with different forms of clinical behavior and the d
Combination therapy for the treatment of Crohn's disease.
Mosli MH and Feagan BG. Expert Opin Biol Ther 2015 - Review. PMID 26211474
INTRODUCTION: Crohn's disease (CD) is an idiopathic inflammatory disorder of the gastrointestinal tract traditionally treated by the step-wise use of corticosteroids, antimetabolites and TNF-α antagonists. ...AREAS COVERED: In this article, we review existing literature regarding the efficacy and safety of combination drug therapy for the management of CD. ...
INTRODUCTION: Crohn's disease (CD) is an idiopathic inflammatory disorder of the gastrointestinal tract traditionally treated …
Ustekinumab to treat Crohn's disease.
Gisbert JP and Chaparro M. Gastroenterol Hepatol 2017 - Review. PMID 29042094
When used as subcutaneous maintenance therapy, the therapeutic benefit of ustekinumab over placebo has been confirmed in both clinical response and remission in patients who have responded clinically to induction therapy. ...The development of drug immunogenicity appears to be rare. In summary, ustekinumab is a promising treatment option in patients with Crohn's disease, as an alternative to anti-TNFα drugs....
When used as subcutaneous maintenance therapy, the therapeutic benefit of ustekinumab over placebo has been confirmed in both clinica …
Treat to target: a proposed new paradigm for the management of Crohn's disease.
Bouguen G, et al. Clin Gastroenterol Hepatol 2015 - Review. PMID 24036054 Free article.
The traditional management of Crohn's disease, which is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, does not improve long-term outcomes of Crohn's disease and places patients at risk for bowel damage. ...This review evaluates current literature on this topic and proposes a definition for the concept of treating to targets for Crohn's disease....
The traditional management of Crohn's disease, which is based on progressive, step-wise treatment intensification with re-eval …
Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
Singh S, et al. Aliment Pharmacol Ther 2018. PMID 29920733 Free article.
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. ...In patients with response to induction therapy, adalimumab (SUCRA, 0.97) and infliximab (SUCRA, 0.68) were ranked highest for maintenance of remission. ...
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). AIM: We …
5,101 results
Jump to page
Feedback